EUCTR2017-002954-35-DK
Active, not recruiting
Phase 1
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk - AMPLITUDE-O
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Type 2 diabetes mellitus
- Sponsor
- sanofi-aventis recherche & développement
- Enrollment
- 5000
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) \> 7%.
- •\-Age 18 years or older with established cardiovascular disease or age 50 years (male), 55 years (female) or older with eGFR \=25 and \<60 mL/min and at least one cardiovascular risk factor.
- •\-Female patients must agree to follow contraceptive guidance.
- •\-Signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 3000
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 2000
Exclusion Criteria
- •\-Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting.
- •\-History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of any type of acute pancreatitis within 3 months prior to screening.
- •\-Personal or family history of medullary thyroid cancer (MTC)
- •\-Hypertension (with a systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg).
- •\-Hospitalization for hypertensive emergency within 3 months prior to randomization
- •\-Planned coronary procedure or surgery after randomization.
- •\-No documented ophthalmologic exam with fundoscopy within 6 months prior to screening
- •\-Retinopathy or maculopathy with treatment, either recent (3 months prior to randomization) or planned during the study
- •\-Treated with any glucagon\-like peptide\-1 (GLP\-1\) receptor agonist products (eg, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or in combination within 3 months prior to screening.
- •\-Use of any DPP4 inhibitor within 3 months prior to screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of Dupilumab in Children with Uncontrolled Asthma (Liberty Asthma Voyage)AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2016-001607-23-HUSanofi-Aventis Recherche & Développement785
Active, not recruiting
Phase 1
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
Active, not recruiting
Phase 1
A Clinical Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2020-000116-30-SEJanssen-Cilag International NV420
Active, not recruiting
Phase 1
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
Active, not recruiting
Phase 1
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2020-006165-11-PLJanssen-Cilag International NV350